About MVA-BN, also known as Imvamune, Imvanex or Jynneos
There are several vaccines available for prevention of smallpox that also provide some protection against monkeypox. A newer vaccine that was developed for smallpox (MVA-BN, also known as Imvamune, Imvanex or Jynneos) was approved in 2019 for use in preventing monkeypox and is not yet widely available.
Schedule
Two doses, 28 days apart, administered sub-cutaneously.
Side Effects
The most common (> 10%) side effects are related to the injection site, e.g., local pain, redness, swelling, induration, and itching. Occasionally, recipients may experience muscle pain, headache, fatigue, nausea and chills.
